SIGA Technologies and Cipla Therapeutics – executive interview

SIGA Technologies and Cipla Therapeutics – executive interview

SIGA Technologies — 4 videos in collection

More on this equity

SIGA Technologies (Nasdaq: SIGA) is a commercial-stage company focusing on health security. Its lead program is oral TPOXX (tecovirimat), which was approved by the FDA in 2018 for the treatment of smallpox and is active against all orthopoxviruses. In this video, SIGA’s CEO, Dr Phillip Gomez, and Garrett Ingram, President, CEO of Cipla Therapeutics, discuss the companies’ recently announced partnership. This collaboration will provide the Biomedical Advanced Research and Development Authority (BARDA) with solutions for its biothreat and public health needs, with a particular focus on tackling antimicrobial resistance (AMR). Find out more about SIGA Technologies (SIGA) in Edison’s initiation report.


You may also be interested in these:

Healthcare

SIGA Technologies – executive interview

Healthcare

SIGA Technologies – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.